Summary
This prespecified analysis of the FOURIER randomised controlled trial examined the cardiovascular efficacy and safety of evolocumab (a PCSK9 inhibitor) across patient subgroups defined by diabetes status, and investigated potential effects on glucose homeostasis and diabetes development. The trial appears to have assessed whether PCSK9 inhibition confers consistent cardiovascular benefit regardless of baseline glucose metabolism, and whether the drug influences diabetes risk. As a large cardiovascular outcomes trial in The Lancet Diabetes & Endocrinology, the analysis likely contributes evidence on the metabolic tolerability of intensive LDL-lowering therapy in high-risk populations.
UK applicability
Findings would be directly relevant to UK clinical practice and NICE guideline development for lipid management and cardiovascular risk reduction, particularly for patients with concurrent or at-risk diabetes. The evidence base supports consideration of PCSK9 inhibitors within NHS treatment pathways, subject to cost-effectiveness and commissioning decisions.
Key measures
Cardiovascular events, lipid panels (LDL-cholesterol), glycaemic markers, incidence of new-onset diabetes, safety outcomes
Outcomes reported
The study evaluated cardiovascular safety and efficacy of evolocumab (a PCSK9 inhibitor) in patients with and without diabetes, and assessed its effects on glycaemic control and risk of new-onset diabetes. Prespecified subgroup analyses examined outcomes stratified by baseline diabetes status.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.